Abstract 399P
Background
Due to the lack of studies on unfit patients with gastric cancer (GC) who did not receive any aggressive cancer treatment—best supportive care (BSC) cases—their long-term prognosis remains unclear, especially for those harboring potentially curable disease (clinical stage [cStage] I–III). Therefore, clinicians sometimes have trouble answering unfit patients or their caregivers when asked questions such as “How long will I live without any anticancer treatment?”. Hence, we conducted this observational study to capture the real-world data of baseline characteristics, provided supportive care, and long-term outcomes for BSC cases.
Methods
Consecutive clinical records of patients with GC diagnosed at Steel Memorial Muroran Hospital (SMMH) from January 2017 to December 2021 were collected and analyzed. We conducted this study with the approval of the Institutional Review Board of SMMH (#J230103). The primary outcome of this study is overall survival (OS).
Results
Of 481 patients diagnosed with GC, 91 (18.9%) were BSC cases; their median age was 85 (range: 46–96) years, and 75.8% were male. BSC cases showed a very high risk of receiving aggressive cancer treatment with a median Age-Adjusted Charlson Comorbidity Index score of 7 and a G-8 score of 7. The median OS for all patients was 3.9 months (95% confidence interval [CI]: 3.0–5.4). The median OS was 12.4, 8.3, and 2.5 months for cStage I, II–III, and IV, respectively. Patients with potentially curable GC (cStage I–III) had significantly longer OS than those with incurable disease (cStage IV), with a hazard ratio for death of 0.29 (95% CI: 0.18–0.47, p<0.0001). The percentage of death by GC in a total number of deaths also increased with increasing stage. Pneumonia and heart failure were the most common cause of death among cases who died other than GC. After diagnosis, cStage I patients were more likely to prefer to stay where they had lived (nursing homes or their own house), while more advanced stage patients chose hospice.
Conclusions
The median OS of BSC cases in poor general condition was ∼1 year for cStage I, 8 months for cStage II–III, and < 3 months for cStage IV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Takada: Financial Interests, Personal, Invited Speaker: Eisai, Janssen, Chugai, Ono, Otsuka, Daiichi Sankyo, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract